SEngine Precision Medicine to Present at Society of Functional Precision Medicine Virtual …

Press release content from Globe Newswire. The AP news staff was not involved in its…

SEngine Precision Medicine to Present at Society of Functional Precision Medicine Virtual …

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) — SEnginePrecision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived tumor organoids, today announced that Chief Medical Officer Astrid L. Margossian, MD, PhD, will present at the Society for Functional Precision Medicine (SFPM) Virtual Monthly Seminar on October 14th at 11:30 am ET.

Dr. Margossian is leading SEngine’s clinical validation initiatives for the PARIS® Test, a CLIA certified cancer organoid based drug sensitivity test for all solid tumors. The presentation is entitled, “Predictive Clinical Value of a CLIA-Approved Organoid Based Drug Sensitivity Test,” and will highlight the data on the PARIS® Test, recently presented at the ASCO 2020 and ACCR 2020 annual meetings, inclusive of organoids sensitivity results, showing clinical correlation with genomics and previous clinical treatments. Registration for the live event is available for free at https://www.sfpm.io/seminars.php.

SFPM’s virtual monthly seminar brings together distinguished guest speakers and through interactive panel discussions and Q&A sessions focuses on these key topics:

  • Demonstrating the clinical utility of functional precision medicine testing
  • Implementing functional testing in precision medicine clinical trials
  • Accelerating the application of functional testing
  • Addressing stakeholder, educational and investment challenges for functional precision medicine

About PARIS® Test
The CLIA certified PARIS® Test is based on the capability to propagate patient-specific cancer tissue as organoids ex vivo and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grown in 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where the path is not clear, such as many metastatic and recurrent cancers, the PARIS test provides crucial information to the treating physicians to match the right drug to the right patient.

About SEngine Precision Medicine
SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine’s CLIA certified PARIS® Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Discover more at SengineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn.

Contact:
Stephanie Carrington
[email protected]
646-277-1282